Genetic aspects of immune-mediated adverse drug effects

被引：18

作者：

Bugelski, PJ ^{[1
]}

机构：

[1] Centocor Inc, Dept Toxicol & Invest Pharmacol, Expt Pathol, Malvern, PA 19355 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2005年 / 4卷 / 01期

关键词：

D O I：

10.1038/nrd1605

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Adverse drug effects (ADEs) are of great importance in medicine and account for up to 5% of all hospital admissions. ADEs can arise from several mechanisms and a wide range of drugs can cause immune-mediated ADEs (IMADEs). For a drug to elicit an IMADE, it must be both immunogenic ( that is, able to sensitize the immune system) and antigenic ( that is, able to evoke a response from a sensitized immune system). Unlike protein therapeutics, small-molecule drugs ( or xenobiotics) are usually neither immunogenic nor antigenic. IMADEs are therefore the result of complex interactions between drug-metabolizing enzymes, immune sensitization and immune effectors. The genetic aspects of this interplay are discussed in this review.

引用

页码：59 / 69

页数：11

共 124 条

[1] Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity [J].

Alfirevic, A ;

Stalford, AC ;

Vilar, FJ ;

Wilkins, EGL ;

Park, BK ;

Pirmohamed, M .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (02) :158-165

[2] Pharmacogenetic and pharmacogenomic studies - Impact on drug discovery and drug development [J].

Alhenc-Gelas, FO ;

Parmentier, L ;

Bisagni, A .

THERAPIE, 2003, 58 (03) :279-282

[3] Life-threatening idiosyncratic drug-induced agranulocytosis in elderly patients [J].

Andrès, E ;

Noel, E ;

Kurtz, JE ;

Loukili, NH ;

Kaltenbach, G ;

Maloisel, F .

DRUGS & AGING, 2004, 21 (07) :427-435

[4]

[Anonymous], 1997, MOL TOXICOLOGY

[5] The nature of selection on the major histocompatibility complex [J].

Apanius, V ;

Penn, D ;

Slev, PR ;

Ruff, LR ;

Potts, WK .

CRITICAL REVIEWS IN IMMUNOLOGY, 1997, 17 (02) :179-224

[6] Glutathione S-transferase polymorphisms in patients with drug eruption [J].

Ates, NA ;

Tursen, U ;

Tamer, L ;

Kanik, A ;

Derici, E ;

Ercan, B ;

Atik, U .

ARCHIVES OF DERMATOLOGICAL RESEARCH, 2004, 295 (10) :429-433

[7] Clinical relevance of pharmaeogenetics [J].

Becquemont, L .

DRUG METABOLISM REVIEWS, 2003, 35 (04) :277-285

[8]

Blümel J, 1999, EUR CYTOKINE NETW, V10, P515

[9] Polymorphism of phase II enzymes: identification of new enzymes and polymorphic variants by database analysis [J].

Board, P ;

Blackburn, A ;

Jermiin, LS ;

Chelvanayagam, G .

TOXICOLOGY LETTERS, 1998, 103 :149-154

[10]

Bougie D, 1997, BLOOD, V90, P407

← 1 2 3 4 5 6 7 8 9 10 →